- Therapeutic Solutions
-
-
-
Therapeutic Solution
Ebola
COVID-19
Oncology
-
-
-
- Medical Animations
- Commercial Services
- Company Infrastructure
- People
- News
- Invest
- Contact
New Publication in JCI Insight 11-22-21: Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties
WHAM 13 ABC – 1-13-21: ROC company reports breakthroughs in drug to treat COVID; focus remains on vaccine
Podcast: Our Body’s Response and Drug Development Policies in the Year of Corona – Harold Smith interviewed on Steve’s Cannabis Show, April 2, 2020.
Press Release: OyaGen, Inc. announces a compound in development with broad antiviral activity against coronaviruses including SARS-CoV-2
Daily Kos – ROC biotech company says lab tests of former cancer drug confirm it stops COVID-19
WHAM13 ABC –ROC biotech company says lab tests of former cancer drug confirm it stops COVID-19
Spectrum News – OyaGen Lab Discovers Compound They Believe Could Help With COVID-19
OyaGen finds an effective therapeutic for Ebola “HIGHLY EFFECTIVE” 1-07-21: Press Release, Publication: A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures
Bennett, R.P., Stewart, R.A., Hogan, P., Ptak, R.G., Mankowski, M.K., Hartman, T.L., Buckheit, R.W., Jr., Snyder, B.A., Salter, J.D., Morales, G.A., Smith, H.C. (2016) An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation. Antiviral Research 136:51-9 PMID:27825797
A&U America’s AIDS Magazine, October, 2015 – Talking “Cure”: What are the barriers to cure research? Part 1 of an interview with Dr. Harold Smith
A&U America’s AIDS Magazine, December 4, 2015 – High Bar: Have we limited cure research by approaching it through a treatment paradigm? Part 2 of an interview with Dr. Harold Smith
Profile in Adjacent Government, November 12, 2015 – Are we standing in our own way on the path to a cure for HIV /AIDS?
Smith HC, (2015) Starting Biotech from Scratch International Innovation. 185:82-85.
Reviews:
Salter J.D., Smith H.C.(2018) Modeling the Embrace of a Mutator: APOBEC Selection of Nucleic Acid Ligands. Trends Biochem Sci. 2018 Aug;43(8):606-622.
Bennett, R.P., Salter, J.D., Smith, H.C. (2018) A New Class of Antiretroviral Enabling Innate Immunity by Protecting APOBEC3 from HIV Vif-Dependent Degradation. Trends in Molecular Medicine Published online March 30, 2018 PMID:29609878. Review
Salter, J.D., Bennett, R.P., Polevoda, B. and Smith, H.C. (2016) The APOBEC Protein Family United by Structure, Divergent in Function. Trends in Biochemical Sciences, Cell Press. 41:578-94 PMID:27283515
Salter JD, Morales GA, Smith HC (2014) Structural insights for HIV-1 therapeutic strategies targeting Vif Trends in Biochemical Sciences September 2014. doi: 10.1016/j.tibs.2014.07.001
Prohaska K, Bennett RP, Salter JD, Smith HC (2014) The multifaceted roles of RNA binding in APOBEC cytidine deaminase functionsWIREs RNA 2014. doi: 10.1002/wrna.1226
© 2003-2022, OyaGen, Inc.
SMARTSite by Site Hub